Nektar Therapeutics NKTR announced that it has initiated a new mid-stage study that will evaluate its pipeline candidate, rezpegaldesleukin (rezpeg), for treating patients with severe to very severe ...
AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 weeks when added to standard statin therapy. The treatment helped 84% of ...
The International Investment Bank (IIB) says it will leave its headquarters in Budapest and return to Russia after the Hungarian government withdrew its representatives from the Moscow-led institution ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback